JamaliMoghadamSiahkali, 60 patient vitamin C late treatment RCT: 25% higher ventilation [p=1] and 31% longer hospitalization [p=0.03] https://c19p.org/jamalimoghadamsiahkali
copied to clipboard
Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19; A Randomized Controlled open-label Clinical Trial
et al., Research Square, doi:10.21203/rs.3.rs-139942/v1 (Preprint)
Small late stage RCT for the addition of vitamin C to HCQ and lopinavir/ritonavir, with 30 treatment and 30 control patients, finding a significant reduction in temperature and a significant improvement in oxygenation after 3 days in the vitamin C group. However, hospitalization time was longer and there was no significant difference in mortality.
|
risk of death, no change, RR 1.00, p = 1.00, treatment 3 of 30 (10.0%), control 3 of 30 (10.0%).
|
|
risk of mechanical ventilation, 25.0% higher, RR 1.25, p = 1.00, treatment 5 of 30 (16.7%), control 4 of 30 (13.3%).
|
|
hospitalization time, 30.8% higher, relative time 1.31, p = 0.03, treatment 30, control 30.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
JamaliMoghadamSiahkali et al., 1/9/2021, Randomized Controlled Trial, Iran, Middle East, preprint, 17 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.